Sensei Biotherapeutics, Inc. (SNSE) News

Sensei Biotherapeutics, Inc. (SNSE): $2.20

0.05 (+2.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SNSE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 423

in industry

Filter SNSE News Items

SNSE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SNSE News Highlights

  • SNSE's 30 day story count now stands at 4.
  • Over the past 11 days, the trend for SNSE's stories per day has been choppy and unclear. It has oscillated between 1 and 3.

Latest SNSE News From Around the Web

Below are the latest news stories about Sensei Biotherapeutics Inc that investors may wish to consider to help them evaluate SNSE as an investment opportunity.

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insiders placed bullish bets worth US$1.0m in the last 12 months

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | January 17, 2022

Sensei Biotherapeutics names Erin Colgan as CFO

No summary available.

Seeking Alpha | January 6, 2022

Sensei Biotherapeutics Announces Executive Promotions

Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officerBOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced two key promotions within the company’s senior management team. Erin Colgan, formerly senior vice president of finance and administration, has been appointed to chief financial officer. Robe

Yahoo | January 6, 2022

Sensei Biotherapeutics Named a Winner of Comparablys Best CEO Award

BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 Best CEOs.

Intrado Digital Media | December 16, 2021

Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award

BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 “Best CEOs.” “What makes Comparably awards so meaningful is that they are based exclusively on employee feedback,” said Elisabeth Colunio, Vice President of Human Resources. “We are thrilled but not surprised to see John recognized as a 2021 B

Yahoo | December 16, 2021

Thomas G. Ricks Acquires 20,000 Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Director Thomas G. Ricks acquired 20,000 shares of the businesss stock in a transaction on Thursday, December 9th. The shares were bought at an average price of $6.62 per share, for a total transaction of $132,400.00. The transaction was disclosed in a legal filing with the SEC, which is available at []

Transcript Daily | December 15, 2021

Sensei Biotherapeutics gains 7% on being added to Nasdaq Biotechnology index

No summary available.

Seeking Alpha | December 14, 2021

Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index

BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it was added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to market open on Monday, December 20, 2021.

Intrado Digital Media | December 13, 2021

Geode Capital Management LLC Raises Stock Position in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE)

Geode Capital Management LLC raised its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 20.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 141,809 shares of the companys stock after acquiring an additional 24,403 shares during the quarter. Geode Capital Management LLC []

Dakota Financial News | November 21, 2021

Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced its participation in a fireside chat during the Piper Sandler 33 rd Annual Virtual Healthcare conference being held from November 29 to December 2, 2021.

Intrado Digital Media | November 19, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4696 seconds.